The new player is compatible with CD-DA, CD-R and CD-RW discs and features a USB-C connection at the rear. Ruark is on a mighty hot streak at the moment and continues to impress us with products that ...

At $12,000, the new Marantz SACD 10 is the best CD/SACD player the company has ever made and it weighs 73 lbs. The SACD 10 is Marantz’s newest CD/SACD player and the successor to the SA-10 ($7,499), ...

Streaming and vinyl may be all the rage, but there are plenty of us who have never let go of our CD collection and enjoy listening to and buying CDs to this day. What Hi-Fi? has been testing and ...

The US buyout firm is pairing with the French pharma giant to buy out its consumer unit. Success here requires much more than cutting costs. Chris Hughes is a Bloomberg Opinion columnist covering ...

Advt The open offer has been triggered by Sanofi and CD&R entering into exclusive negotiations for the potential sale and purchase of a 50 per cent controlling stake in Opella, Sanofi's consumer ...

Global investment firm CD&R on Monday announced an open offer to acquire a 26 per cent stake in Sanofi Consumer Healthcare India Ltd for an aggregate of up to Rs 2,983 crore. The development follows ...

Global investment firm CD&R on Monday announced an open offer to acquire a 26% stake in Sanofi Consumer Healthcare India Ltd. for an aggregate of up to Rs 2,983 crore. The development follows Sanofi ...

Sanofi said on Monday (Oct 21) it had entered exclusive talks for the sale of a 50 per cent controlling stake in its consumer health business Opella to US private equity firm Clayton Dubilier & Rice ...

PARIS, Oct 21 (Reuters) - French drugmaker Sanofi (SASY.PA), opens new tab said on Monday it had entered exclusive talks to sell a 50% controlling stake in its consumer health business Opella to U ...

French pharmaceutical group Sanofi and US private equity firm Clayton Dubilier & Rice (CD&R) have entered exclusive negotiations regarding the partial takeover of Sanofi subsidiary Opella.

The deal would allow Sanofi to focus on its more lucrative, but riskier, innovative drugs and vaccines, and CD&R to take a 50% controlling stake in a business that is home to brands such as ...